BioDelivery Sciences Announces New Drug Submission In Canada For BEMA Fentanyl

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the filing of a New Drug Submission (NDS) to Health Canada, the regulatory authority in Canada, for BEMA Fentanyl, also known as fentanyl buccal soluble film. BEMA Fentanyl is marketed in the U.S. as ONSOLIS, and the Canadian tradename is to be determined. BEMA Fentanyl was submitted to Health Canada by Meda Valeant Pharma Canada Inc.

More: continued here

Filed under: Cancer on October 5th, 2009